Shukra Pharmaceuticals issued a corrigendum on September 22, 2026, to its postal ballot notice dated August 22, 2026. The revision substitutes the original Independent Auditor's Certificate with a revised version dated September 16, 2026, to comply with specific numerical disclosure requirements under Regulation 45 of the SEBI (LODR) Regulations, 2015.

The original notice sought shareholder approval for altering the Main Object Clause of the Memorandum of Association and changing the company name from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited." The corrigendum was necessitated by observations from BSE Limited regarding the format of the auditor's certificate attached to the explanatory statement.

Revised Auditor's Certificate Details

The statutory auditors, M/s Shah Sanghvi & Associates, Chartered Accountants, issued the revised certificate to align with the mandated layout. The certificate confirms that at least one year has elapsed since the last name change. It also certifies compliance with Regulation 45(1)(b), which requires that at least fifty percent of total revenue in the preceding one-year period be accounted for by the new activity suggested by the new name, or that at least fifty percent of assets are invested in the new activity.

The revised certificate provides detailed financial data for the period from July 1, 2025, to June 30, 2026. While income from the new medical technology activity was nil, the company demonstrated asset investment compliance.

Shareholder Voting Instructions

The remote e-voting period commenced on August 28, 2026, and concludes on September 26, 2026. To ensure transparency following the issuance of the corrigendum, shareholders who have already voted are permitted to cast their vote again via the NSDL e-voting system.

• If a shareholder votes again during the active window, the latest vote will supersede and cancel the previous vote.
• Shareholders who do not wish to change their previously recorded vote need not take any action; their initial vote remains valid.
• The corrigendum and revised certificate are available on the company website and stock exchange platforms.

What the Numbers Show

The financial data reveals a divergence between revenue generation and asset allocation regarding the proposed business shift. For the fiscal year ending June 30, 2026, the company reported zero income from its new medical technology activity, with 100% of revenue derived from its legacy pharmaceutical operations. However, it met the regulatory threshold for name change by investing ₹5,058.31 lakh, representing 51.04% of its total assets, into the new medical technology line of business. This indicates a strategic capital deployment ahead of operational revenue realization in the new segment.

Shukra Pharmaceuticals has filed the notice for its 33rd Annual General Meeting (AGM) with stock exchanges. The meeting is scheduled for Monday, September 28, 2026, at 12:00 pm via Video Conferencing.

The company previously rescheduled the AGM from September 22, 2026, citing administrative exigencies. The notice confirms the revised date and outlines the ordinary business to be transacted.

Agenda Items

The AGM agenda includes four key items:

1. Adoption of Financials: Consideration and adoption of the audited financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors.
2. Dividend Declaration: Approval and declaration of a final dividend of ₹0.01 per equity share of face value ₹1 each for FY26. This represents a 1% dividend payout.
3. Director Re-appointment: Re-appointment of Ms. Sanskruti Patel (DIN: 07108631) as an Executive Director. She retires by rotation and offers herself for re-appointment.
4. Additional Independent Director: Regularisation of the appointment of Mr. Dinesh Chauhan (DIN: 11456530) as an Additional Independent Director. This requires a Special Resolution.

Schedule and Logistics

The Register of Members and Share Transfer Books will remain closed from Tuesday, September 22, 2026, to Monday, September 28, 2026 (both days inclusive). This closure facilitates the preparation of the list of members entitled to attend and vote at the AGM.

The remote e-voting period and cut-off date will be aligned with the revised AGM schedule. Specific details regarding e-voting will be provided in the final notice circulated to shareholders.

All other appointments approved in the board meeting dated August 22, 2026, remain unchanged. This includes the appointment of Mrs. Rupal Patel, Practicing Company Secretary, as Scrutinizer.